Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
YS Biopharma Announces Name Change to LakeShore Biopharma 2024-05-24 19:30
YS Biopharma Announces Results of Extraordinary General Meeting 2024-05-22 04:15
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer 2024-05-08 04:20
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule 2024-04-29 20:00
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024 2024-04-19 19:00
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine 2024-04-18 20:00
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024 2024-04-16 20:00
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine 2024-04-09 20:00
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility 2024-04-03 20:00
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries 2024-03-05 21:00
YS Biopharma Announces Appointment of New Directors 2024-02-14 20:50
YS Biopharma Announces US$40 Million Private Placement Financing 2024-02-09 19:30
YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024 2024-01-23 06:00
YS Biopharma Announces Changes to its Board Committees 2024-01-08 21:00
YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting 2023-12-21 05:30
/DISREGARD RELEASE: YS Biopharma/ 2023-12-21 05:15
YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine 2023-10-31 20:30
YS Biopharma Announces Receipt of Nasdaq Notice 2023-10-26 20:30
YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine 2023-09-26 20:30
YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection 2023-09-15 20:30
1 2